Mazzone T et al. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies.

Lancet. 2008;371:1800.

Stratton IM et al. Association of glycaemia with macrovascular and microvascular complications of type 2

diabetes (UKPDS 35): prospective observationalstudy. BMJ. 2000; 321:405.

The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on

the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J

Med. 1993;329:977.

The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications

Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of

intensive therapy [published correction appears in N EnglJ Med. 2000;342:1376]. N EnglJ Med. 2000;342:381.

Martin CL et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial

completion. Diabetes Care. 2006;29:340.

Nathan DM et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl

J Med. 2005;353:2643.

Holman RR et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N EnglJ Med. 2008;359:1577.

Retnakaran R, Zinman B. Type 1 diabetes, hyperglycaemia, and the heart. Lancet. 2008;371:1790.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin

compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

[published correction appears in Lancet. 1999;354:602]. Lancet. 1998;352:837.

Gaede P et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J

Med. 2003; 348:383.

American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care. 2015;38 (Suppl 1):

S49–S57.

American Diabetes Association. Glycemic targets. Diabetes Care. 2015;38(Suppl 1):S33–S40.

Handelsman Y et al. American association of clinical endocrinologists and American college of endocrinology—

Clinical practice guidelines for developing A diabetes mellitus comprehensive care plan—2015. Endocr Pract.

2015:21(Suppl 1):1–87.

Action to Control Cardiovascular Risk in Diabetes Study Group et al. Effects of intensive glucose lowering in type

2 diabetes. N EnglJ Med. 2008;358:2545.

Riddle MC et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year

follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010;33:983.

ADVANCE Collaborative Group et al. Intensive blood glucose control and vascular outcomes in patients with

type 2 diabetes. N EnglJ Med. 2008;358:2560.

Duckworth W et al. Glucose control and vascular complications in veterans with type 2 diabetes [published

corrections appear in N Engl J Med. 2009;361:1028; N Engl J Med. 2009;361:1024]. N Engl J Med.

2009;360:129.

Hayward RA et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N EnglJ Med.

2015;372(23):2197–2206.

Skyler JS et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the

ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association

and a scientific statement of the American College of Cardiology Foundation and the American Heart

Association [published correction appears in Diabetes Care. 2009;32:754]. Diabetes Care. 2009;32:187.

Skyler JS. Primary and secondary prevention of type 1 diabetes. Diabet Med. 2013;30(2):161–169.

Knowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N EnglJ

Med. 2002;346:393.

Diabetes Prevention Program Research Group et al. 10-year follow-up of diabetes incidence and weight loss in

the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677.

American Diabetes Association. Prevention or delay of type 2 diabetes. Diabetes Care. 2015;38(Suppl 1):S31–

S32.

American Diabetes Association. Foundations of care: Education, nutrition, physical activity, smoking cessation,

psychosocial care, and immunization. Diabetes Care. 2015;38(Suppl 1):S20–S30.

Evert AB et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care.

2014;37(Suppl 1):S120–S143.

Franz MJ et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of

diabetes and related complications. Diabetes Care. 2003;26(Suppl 1):S51.

Franz MJ et al. Evolution of diabetes medical nutrition therapy. Postgrad Med J. 2003;79:30.

Sigal RJ et al. Physical activity/exercise and type 2 diabetes. Diabetes Care. 2004;27:2518.

Wasserman DH, Zinman B. Exercise in individuals with IDDM. Diabetes Care. 1994;17:924.

Goldstein DE et al. Tests of glycemia in diabetes. Diabetes Care. 2004;27(Suppl 1):S91.

Buckingham B et al. Real-time continuous glucose monitoring. Curr Opin Endocrinol Diabetes Obes. 2007;14:288.

Gorus F et al. How should HbA1c measurements be reported? Diabetologia. 2006;49:7.

Nathan DM et al. Translating the A1C assay into estimated average glucose values [published correction appears

in Diabetes Care. 2009;32:207]. Diabetes Care. 2008;31:1473.

Ng JM et al. The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic

kidney disease. Diabetes Care. 2010;33:2310.

Davie SJ et al. Effect of vitamin C on glycosylation of proteins. Diabetes. 1992;41:167.

International Expert Committee. International Expert Committee report on the role of the A1C assay in the

diagnosis of diabetes. Diabetes Care. 2009;32:1327–1334.

Nolte MS. Pancreatic hormones and antidiabetic drugs. In: Katzung B et al, eds. Basic and Clinical

Pharmacology. 11th ed. New York: Lange Medical Books/McGraw-Hill; 2009:727.

DeFelippes MR et al. Insulin chemistry and pharmacokinetics. In: Porte D Jr et al, eds. Ellenberg & Rifkin’s

Diabetes Mellitus. 6th ed. New York, NY: McGraw-Hill; 2003:481.

Rabkin R et al. The renal metabolism of insulin. Diabetologia. 1984;27:351.

Binder C, Brange J. Insulin chemistry and pharmacokinetics. In: Porte D Jr et al, eds. Ellenberg & Rifkin’s

Diabetes Mellitus. 5th ed. Stamford, CT: Appleton & Lange; 1997.

Burge MR, Schade DS. Insulins. Endocrinol Metab Clin North Am. 1997;26:575.

Garg S et al. Rapid-acting insulin analogues in Basalbolus regimens in type 1 diabetes mellitus. Endocr Pract.

2010;16:486.

Raskin P et al. A comparison of insulin lispro and buffered regular human insulin administered via continuous

subcutaneous insulin infusion pump. J Diabetes Complications. 2001;15:295.

Humalog [package insert]. Indianapolis, IN: Eli Lilly and Company; November 2015.

Novolog [package insert]. Plainsboro, NJ: Novo Nordisk; February 2015.

Apidra [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; October 2015.

Afrezza [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; May 2015.

Humulin R U500 [package insert]. Indianapolis, IN: Eli Lilly and Company; September 2014.

As U-500 insulin safety concerns mount, it’s time to rethink safe use of strengths above U-100 ISMP. Available

at https://www.ismp.org/newsletters/acutecare/showarticle.aspx?id=62. Accessed June 2015.

Lantus [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; February 2015.

Bolli GB, Owens DR. Insulin glargine. Lancet. 2000;356:443.

Lepore M et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin

analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

Diabetes. 2000;49:2142.

Dunn CJ et al. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs.

2003;63:1743.

Raskin P et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human

100.

101.

102.

103.

104.

105.

106.

107.

108.

insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care. 2000;23:1666.

Toujeo [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; February 2015.

Levemir [package insert]. Bagsvsrd, Denmark: Novo Nordisk Inc; Feburary 2015.

Kurtzhals P. Pharmacology of insulin detemir. Endocrinol Metab Clin North Am. 2007;36(Suppl 1):14.

Plank J et al. A double-blind, randomized dose-response study investigating the pharmacodynamic and

pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28:1107.

Heise T et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine

in people with type 1 diabetes. Diabetes. 2004;53:1614.

Tresiba [package insert]. Bagsvsrd, Denmark: Novo Nordisk; September 2015.

Turnheim K. Basic aspects of insulin pharmacokinetics. In: Brunetti P, Waldhausl W, eds. Advanced Models for

the Therapy of Insulin-Dependent Diabetes. New York, NY: Raven Press; 1987:91.

Koivisto VA, Felig P. Alterations in insulin absorption and in blood glucose control associated with varying insulin

injection sites in diabetic patients. Ann Intern Med. 1980;92:59.

American Diabetes Association. Continuous subcutaneous insulin infusion. Diabetes Care. 2004;27(Suppl 1):S110.

American Diabetes Association. 2014 Consumer Guide. Diabetes Forecast, January 2014.

Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of

insulin pump therapy in type 1 diabetes. Diabetes Care. 2002; 25:593.

Mooradian AD et al. Narrative review: a rational approach to starting insulin therapy. Ann Intern Med.

2006;145:125.

DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus:scientific review. JAMA.

2003; 289:2254.

Ashwell SG et al. Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using

mealtime insulin aspart. Diabet Med. 2006;23:879.

Bott S et al. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over

time with twice daily administration in subjects with type 1 diabetes. Diabet Med. 2006;23:522.

Porcellati F et al. Comparison of pharmacokinetic and dynamics of the long-acting insulin analogs glargine and

detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study [published correction

appears in Diabetes Care. 2008;31:188]. Diabetes Care. 2007;30:2447.

Pickup J et al. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin

injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2002;324:705.

Campbell PJ et al. Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus.

Accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone

secretion. N EnglJ Med. 1985;312:1473.

Walsh J, Roberts R. Pumping Insulin: Everything You Need For Success On A Smart Insulin Pump. 4th ed. San

Diego, CA: Torrey Pines Press; 2006.

Inzucchi S et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient centered approach update to a

position statement of the American Diabetes Association and the European Association for the study of

diabetes. Diabetes Care. 2015; 38 140–149

Siminerio L et al. Strategies for Insulin Injection Therapy in Diabetes Self-Management. American Association

of Diabetes Educators (AADE), April 2001. Available at https://www.diabeteseducator.org/docs/defaultsource/legacy-docs/_resources/pdf/research/aade_meded.pdf?sfvrsn=2

Lee WC et al. Medication adherence and the associated health- economic impact among patients with type 2

diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin

Ther. 2006;28(10):1712–1725.

Grabner M et al. Clinical and economic outcomes among patients with diabetes mellitus initiating insulin glargine

pen versus vial. Postgrad Med. 2013;125(3):204–213.

Pisano, M. Overview of insulin and non-insulin delivery devices in the treatment of diabetes. P T.

2014;39(12):866–873.

American Diabetes Association. Insulin administration. Diabetes Care. 2004;27(Suppl 1):S106.

Malanda UL et al. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using

insulin. Cochrane Database Syst Rev. 2012;(1):CD005060

Walsh J et al. Using Insulin: Everything You Need for Success With Insulin. San Diego, CA: Torrey Pine Press;

2003.

Perriello G et al. The effect of asymptomatic nocturnal hypoglycemia on glycemic control in diabetes mellitus. N

EnglJ Med. 1988;319:1233.

109.

110.

111.

112.

113.

114.

115.

116.

117.

118.

119.

120.

121.

122.

123.

124.

125.

126.

127.

128.

129.

130.

131.

132.

133.

134.

Fanelli CG et al. Administration of neutral protamine hagedorn insulin at bedtime versus with dinner in type 1

diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial. Ann

Intern Med. 2002;136:504.

Rybicka M et al. The dawn phenomenon and the Somogyi effect—two phenomena of morning hyperglycaemia.

Endokrynol Pol. 2011;62(3):276–284.

Ratner RE et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S.

Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care. 2000;23:639.

De Leeuw I et al. Insulin detemir used inbasal-bolus therapy in people with type 1 diabetes is associated with a

lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin.

Diabetes Obes Metab. 2005;7:73.

Hermansen K et al. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin. Diabetes

Care. 2001;24:296.

Bolli GB, Gerich JE. The “dawn phenomenon”—a common occurrence in both non-insulin-dependent and

insulin-dependent diabetes mellitus. N EnglJ Med. 1984;310:746.

Wolfsdorf J et al. Diabetic ketoacidosis in children and adolescents with diabetes. Pediatr Diabetes.

2009;10(Suppl 12):118.

Silverstein J et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes

Association. Diabetes Care. 2005;28:186.

Chiang JL et al. Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position

statement of the American Diabetes Association. Diabetes Care. 2014;37:203422054.

Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Effect of

intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent

diabetes mellitus. J Pediatr. 1994;125:177.

White NH et al. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the

conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr. 2001;139:804.

Siminerio LM et al. Care of young children with diabetes in the child care setting: a position statement of the

American Diabetes Association. Diabetes Care. 2014;37:2834–2842

Murphy NP et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human

insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care. 2003;26:799.

Chase HP et al. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes

using insulin glargine and neutral protamine Hagedorn insulin. J Pediatr. 2003;143:737.

Phillip M et al. Use of insulin pump therapy in the pediatric age-group: consensus statement from the European

Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International

Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the

European Association for the Study of Diabetes. Diabetes Care. 2007;30:1653.

McMahon SK et al. Insulin pump therapy in children and adolescents: improvements in key parameters of

diabetes management including quality of life. Diabet Med. 2005; 22:92.

Patton SR et al. Survey of insulin site rotation in youth with type 1 diabetes mellitus. J Pediatr Health Care.

2010;24:365.

Asvold BO et al. Cognitive function in type 1 diabetic adults with early exposure to severe hypoglycemia: a 16-

year follow-up study. Diabetes Care. 2010;33:1945.

Davis EA et al. Impact of improved glycaemic control on rates of hypoglycaemia in insulin dependent diabetes

mellitus. Arch Dis Child. 1998;78:111.

Jones TW et al. Decreased epinephrine responses to hypoglycemia during sleep. N EnglJ Med. 1998;338:1657.

Deiss D et al. Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous

subcutaneous glucose monitoring in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2007;8:157.

American Diabetes Association. Living With Diabetes. When you’re sick. Available at

http://www.diabetes.org/living-with-diabetes/treatment-and-care/whos-on-your-health-careteam/when-youre-sick.html. Accessed June 1, 2015.

Rubenstein AH, Spitz I. Role of the kidney in insulin metabolism and excretion. Diabetes. 1968;17:161.

Rabkin R et al. Effect of renal disease on renal uptake and excretion of insulin in man. N Engl J Med.

1970;282:182.

Falciglia M et al. Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. Crit

Care Med. 2009;37:3001.

Kosiborod M et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients

135.

136.

137.

138.

139.

140.

141.

142.

143.

144.

145.

146.

147.

148.

149.

150.

151.

152.

153.

154.

155.

156.

157.

158.

159.

160.

161.

162.

hospitalized with acute myocardial infarction. JAMA. 2009;301:1556.

Kosiborod M et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial

infarction: implications for patients with and without recognized diabetes. Circulation. 2005;111:3078.

Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute

myocardial infarction in patients with diabetes mellitus. 5 DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion

in Acute Myocardial Infarction) Study Group. BMJ. 1997;314:1512.

Malmberg K et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute

myocardial infarction (DIGAMI-2): effects on mortality and morbidity. Eur Heart J. 2005;26:650.

Metha SR et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment

elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA. 2005;293:437.

Cheung NW et al. The Hyperglycemia Intensive Insulin Infusion in Infarction (HI-5) Study: a randomized

controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care. 2006;29:765.

van den Berghe G et al. Intensive insulin therapy in the critically ill patients. N EnglJ Med. 2001;345:1359.

van den Berghe G et al. Intensive insulin therapy in the medical ICU. N EnglJ Med. 2006;354:449.

NICE-SUGAR Study Investigators et al. Intensive versus conventional glucose control in critically ill patients. N

EnglJ Med. 2009;360:1283.

Pittas AG et al. Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled

trials. Arch Intern Med. 2004;164:2005.

Wiener RS et al. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis [published

correction appears in JAMA. 2009;301:936]. JAMA. 2008;300:933.

Bruno A et al. Normal glucose values are associated with a lower risk of mortality in hospitalized patients.

Diabetes Care. 2008;31:2209.

McAlister FA et al. The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital

with community-acquired pneumonia. Diabetes Care. 2005;28:810.

Baker EH et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute

exacerbations of chronic obstructive pulmonary disease. Thorax. 2006;61:284.

Magaji V, Johnston J. Inpatient management of hyperglycemia and diabetes. Clin Diabetes. 2011;29(1):3–9.

Clement S et al. Management of diabetes and hyperglycemia in hospitals [published correction appears in

Diabetes Care. 2004;27:1255]. Diabetes Care. 2004;27:553.

Goldberg PA et al. Implementation of a safe and effective insulin infusion protocol in a medical intensive care

unit. Diabetes Care. 2004;27:461.

Markovitz LJ et al. Description and evaluation of a glycemic management protocol for patients with diabetes

undergoing heart surgery. Endocr Pract. 2002;8:10.

Food and Drug Administration. FDA Public Health Notification: Potentially Fatal Errors with GDH-PQQ*

Glucose Monitoring Technology. August 13,2009.

http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/ucm176992.htm

Accessed July 1, 2015.

Parekh B. The mechanism of dead-in-bed syndrome and other sudden unexplained nocturnal deaths. Curr

Diabetes Rev. 2009;5:210.

Cryer PE, Gerich JE. Hypoglycemia in insulin-dependent diabetes mellitus: interplay of insulin excess and

compromised glucose regulation. In: Porte D Jr et al, eds. Ellenberg & Rifkin’s Diabetes Mellitus. 6th ed. New

York, NY: McGraw-Hill; 2003:523.

de Galan BE et al. Pathophysiology and management of recurrent hypoglycaemia and hypoglycaemia

unawareness in diabetes. Neth J Med. 2006;64:269.

Kitabchi AE et al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32:1335.

Salpeter SR et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Cochrane Database Syst Rev. 2010;(4):CD002967.

Ennis ED, Kreisberg RA. Diabetic ketoacidosis. In: Porte D Jr et al, eds. Ellenberg & Rifkin’s Diabetes

Mellitus. 6th ed. New York, NY: McGraw-Hill; 2003:573.

Viallon A et al. Does bicarbonate therapy improve the management of severe diabetic ketoacidosis? Crit Care

Med. 1999;27:2690.

Kirpichnikov D et al. Metformin: an update. Ann Intern Med. 2002;137:25.

Zhou G et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest.

2001;108:1167.

Miller RA, Birnbaum MJ. An energetic tale of AMPK-independent effects of metformin. J Clin Invest.

163.

164.

165.

166.

167.

168.

169.

170.

171.

172.

173.

174.

175.

176.

177.

178.

179.

180.

181.

182.

183.

184.

185.

186.

187.

188.

189.

190.

191.

192.

193.

194.

195.

196.

2010;120:2267.

Schimmack G et al. AMP-activated protein kinase: role in metabolism and therapeutic implications. Diabetes

Obes Metab. 2006;8:591.

Glucophage and Glucophage XR [package insert]. New York, NY: Bristol-Myers Squibb Company; January

2009.

Tahrani AA et al. Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ.

2007;335:508.

Salpeter SR et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus:

systematic review and meta-analysis. Arch Intern Med. 2003;163:2594.

Fitzgerald E et al. Metformin associated lactic acidosis. BMJ. 2009;339:b3660.

Shu Y et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin

Invest. 2007;117:1422.

Shaw JS et al. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med.

2007;24:1160.

Prandin [package insert]. Princeton, NJ: Novo Nordisk; May 2010.

Starlix [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2008.

Nan DN et al. Acute hepatotoxicity caused by repaglinide. Ann Intern Med. 2004;141:823.

Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide

and nateglinide. Clin Pharmacokinet. 2007;46:93.

Black C et al. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;

(2):CD004654.

Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes:scientific review. JAMA. 2002;287:360.

Groop LC. Sulfonylureas in NIDDM. Diabetes Care. 1992;15:737.

Groop LC et al. Effect of sulfonylurea on glucose-stimulated insulin secretion in healthy and non-insulin

dependent diabetic subjects: a dose-response study. Acta Diabetol. 1991;28:162.

Wahlin-Boll E et al. Impaired effect of sulfonylurea following increased dosage. Eur J Clin Pharmacol.

1982;22:21.